Answers are grounded in this paper and cite their sources.
Background: Chemotherapy resistance has become a problem for the treatment of breast cancer patients.This study aimed to investigate whether astragaloside IV (AS-IV) has synergistic effects to enhance Paclitaxel (PTX) chemosensitivity in breast cancer cells.Materials and Methods: CCK-8 assays were performed to evaluate the sensitivity of the cell to AS-IV and PTX.The flow cytometric analysis of Annexin-V-fluoresceine isothiocyanate (FITC)/propidium iodide (PI) staining was carried out to evaluate cell apoptosis.The western blotting assay was used to measure the apoptosis-related proteins and Nrf-2 levels.ROS levels were measured using Dichlorofluorescein (DCF) assay.Results: AS-IV enhances PTX chemosensitivity in MDA-MB-231 and MCF-7 cells by enhancing the inhibitory effect of cell viability and promotion effect on cell apoptosis of PTX.The synergistic effects of AS-IV to PTX could decrease the Nrf-2 expression and increase the ROS levels.Nrf-2 signaling was related to ROS generation. Conclusion: AS-IV may enhance PTX chemosensitivity in breast cancer via regulatingNrf-2 signaling.AS-IV might be used as a potential adjuvant drug to increase PTX sensitivity in breast cancer cells.
No takes yet. Share an insight, caveat, or question.
Runwei et al. (2025) studied this question.